Cytokinetics
CYTK
253 hedge funds and large institutions have $3.55B invested in Cytokinetics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 97 increasing their positions, 80 reducing their positions, and 38 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 80
0.64% less ownership
Funds ownership: 114.33% → 113.68% (-0.64%)
3% less funds holding
Funds holding: 262 → 253 (-9)
7% less capital invested
Capital invested by funds: $3.83B → $3.55B (-$285M)
21% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 38
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
47% less call options, than puts
Call options by funds: $7.6M | Put options by funds: $14.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$27.5M |
| 3 |
BlackRock
New York
|
+$27.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$19.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$34.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$33.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$26M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$22.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$18.1M |
CYTK Hedge Fund Activity: Q2 2023 in Review
253 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2023, worth a combined $3.55B — down 7.4% from $3.83B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of CYTK and 30 opened new positions — a net loss of 8 holders — while 80 trimmed existing stakes and 97 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.3M. The largest seller was Bank of America, cutting an estimated $34.9M.
- 253 institutional investors held Cytokinetics (CYTK) as of Q2 2023, down from 262 in Q1 2023.
- Funds reported $3.55B of Cytokinetics stock for Q2 2023, down 7.4% quarter-over-quarter.
- 30 funds opened new Cytokinetics positions in Q2 2023 and 38 closed out, a net change of -8 holders.
- The largest Cytokinetics buyer in Q2 2023 was Citadel Advisors, an estimated $33.3M added.
- The largest Cytokinetics seller in Q2 2023 was Bank of America, an estimated $34.9M sold.
Based on aggregated 13F filings for Q2 2023.